ARCT ▼ -2.9% - Arcturus Therapeutics Holdings Inc. $ARCT Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform Arcturus Therapeutics fell 2.9% today following the company's announcement of interim Phase 2 results for its OTC program and the introduction of its LUNAR 2.0 next-generation mRNA delivery platform. The market's modest decline suggests investors may have been disappointed by the clinical data or viewed the new platform announcement as insufficient to offset any setbacks in the existing trial results. 23-SEP-2026 04:01 PM ET